ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial

BACKGROUND: Rheumatoid arthritis (RA) is a chronic, debilitating autoimmune condition characterized by joint synovial inflammation. Current treatments include methotrexate (MTX), biologic agents, and Janus kinase (JAK) inhibitors. However, these agents are not efficacious in all patients and there a...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Tsutomu, Tanaka, Yoshiya, Erdman, Jay, Kaneko, Yuichiro, Saito, Masako, Higashitani, Chieri, Smulders, Ronald, Lademacher, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7579887/
https://www.ncbi.nlm.nih.gov/pubmed/33087159
http://dx.doi.org/10.1186/s13075-020-02336-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7579887/
https://www.ncbi.nlm.nih.gov/pubmed/33087159
http://dx.doi.org/10.1186/s13075-020-02336-3

Ejemplares similares